The mechanism by which dagglitazine protects cardiovascular and renal function in patients with type 2 diabetes mellitus
10.3760/cma.j.issn.1008-6706.2021.04.006
- VernacularTitle:达格列净对2型糖尿病患者心血管和肾功能的保护机制研究
- Author:
Yu WANG
;
Chenxi SHENG
- From:
Chinese Journal of Primary Medicine and Pharmacy
2021;28(4):504-509
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the protective effect of dagglitazine on cardiovascular and renal function in patients with type 2 diabetes mellitus.Methods:A total of 200 patients with type 2 diabetes patients with poor blood glucose control who received treatment in Huxi Hospital Affiliated to Jining Medical University (Shanxian Central Hospital) from January to December 2019 were included in this study. They were randomly assigned to receive treatment with either metformin ( n = 100, control group) or dagglitazine ( n = 100, observation group) based on diet control and exercise therapy for 12 weeks. Before and after treatment, blood glucose, blood lipid, blood pressure, body mass index, cardiac function and renal function were compared between the control and observation groups. Adverse reactions were also monitored in each group. Results:After treatment, blood glucose, blood lipid, body mass index, cardiac function and renal function in each group were improved compared with before treatment (all P < 0.05). Fasting blood glucose, 2-h postprandial blood glucose, glycosylated hemoglobin, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride, low density lipoprotein cholesterol, body mass index, left ventricular end diastolic diameter, serum creatinine, uric acid and cystatin C in the observation group were (6.48 ± 0.72) mmol/L, (8.03 ± 0.77) mmol/L, (6.16 ± 0.63)%, (126.03 ± 3.86) mmHg, (75.62 ± 2.87) mmHg, (3.83 ± 0.17) mmol/L, (2.21 ± 0.36) mmol/L, (2.34 ± 0.15) mmol/L, (23.03 ± 0.55) kg/m 2, (52.10 ± 2.13) mm, (39.97 ± 1.62) μmol/L, (237.17 ± 20.34) μmol/L, (0.64 ± 0.06) mg/L, respectively, which were significantly lower than (8.01 ± 0.84) mmol/L, (10.03 ± 0.90) mmol/L, (7.30 ± 0.72)%, (130.06 ± 4.79) mmHg, (79.60 ± 3.19) mmHg, (4.67 ± 0.37) mmol/L, (2.51 ± 0.57) mmol/L, (2.74 ± 0.19) mmol/L, (24.03 ± 0.60) kg/m 2, (57.22 ± 1.74) mm, (80.00 ± 6.88) μmol/L, (281.62 ± 40.52) μmol/L, (0.76 ± 0.09) mg/L, t = 13.850, 16.866, 11.933, 6.549, 9.263, 20.879, 4.469, 16.982, 12.410, 18.634, 10.626, 9.804, 18.876, all P < 0.001). After treatment, high density lipoprotein cholesterol, left ventricular ejection fraction, and the average distance walked by patients during the 6-min walk test in the observation group were (2.47 ± 0.15) mmol/L, (39.97 ± 1.62)%, (366.50 ± 17.74) m, which were significantly superior to those in the control group [(1.70 ± 0.20) mmol/L, (36.77 ± 1.21)%, (323.70 ± 12.48) m, t = 30.255, 16.435, 19.733, all P < 0.001). There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusion:Dagglitazine protects cardiovascular and renal function by reducing blood glucose, blood pressure, blood lipid, serum creatinine, serum uric acid levels and decreasing body mass index in patients with type 2 diabetes mellitus.
